Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Low-grade mucosal inflammation and immune activation are involved in the pathogenesis of irritable bowel syndrome (IBS).

Who Took Part

The study group was 90 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A total of 90 IBS patients participated in this double-blind, randomized, placebo-controlled study.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

The IBS severity score system (IBSSS) and IBS-specific QoL questionnaires were used at the baseline and postintervention.

What Was Measured

PubMed files the paper under topics including Diarrhea, Flatulence, Irritable Bowel Syndrome, Quality of Life, Surveys and Questionnaires and Vitamin D.

Author keywords: IBS severity score, gastrointestinal symptoms and health-related quality of life.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 90 patients.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Neurogastroenterology and motility), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.